MicroRNA characteristics in epithelial ovarian cancer
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
MicroRNA characteristics in epithelial ovarian cancer. / Prahm, Kira Philipsen; Høgdall, Claus Kim; Karlsen, Mona Aarenstrup; Christensen, Ib Jarle; Novotny, Guy Wayne; Høgdall, Estrid.
In: Plos One, Vol. 16, No. 6, e0252401, 2021, p. 1-18.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - MicroRNA characteristics in epithelial ovarian cancer
AU - Prahm, Kira Philipsen
AU - Høgdall, Claus Kim
AU - Karlsen, Mona Aarenstrup
AU - Christensen, Ib Jarle
AU - Novotny, Guy Wayne
AU - Høgdall, Estrid
N1 - Publisher Copyright: © 2021 Prahm et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2021
Y1 - 2021
N2 - The purpose of the current study was to clarify differences in microRNA expression according to clinicopathological characteristics, and to investigate if miRNA profiles could predict cytoreductive outcome in patients with FIGO stage IIIC and IV ovarian cancer. Patients enrolled in the Pelvic Mass study between 2004 and 2010, diagnosed and surgically treated for epithelial ovarian cancer, were used for investigation. MicroRNA was profiled from tumour tissue with global microRNA microarray analysis. Differences in miRNA expression profiles were analysed according to histologic subtype, FIGO stage, tumour grade, type I or II tumours and result of primary cytoreductive surgery. One microRNA, miR-130a, which was found to be associated with serous histology and advanced FIGO stage, was also validated using data from external cohorts. Another seven microRNAs (miR-34a, miR-455-3p, miR-595, miR-1301, miR-146-5p, 193a-5p, miR-939) were found to be significantly associated with the clinicopathological characteristics (p ≤ 0.001), in our data, but mere not similarly significant when tested against external cohorts. Further validation in comparable cohorts, with microRNA profiled using newest and similar methods are warranted.
AB - The purpose of the current study was to clarify differences in microRNA expression according to clinicopathological characteristics, and to investigate if miRNA profiles could predict cytoreductive outcome in patients with FIGO stage IIIC and IV ovarian cancer. Patients enrolled in the Pelvic Mass study between 2004 and 2010, diagnosed and surgically treated for epithelial ovarian cancer, were used for investigation. MicroRNA was profiled from tumour tissue with global microRNA microarray analysis. Differences in miRNA expression profiles were analysed according to histologic subtype, FIGO stage, tumour grade, type I or II tumours and result of primary cytoreductive surgery. One microRNA, miR-130a, which was found to be associated with serous histology and advanced FIGO stage, was also validated using data from external cohorts. Another seven microRNAs (miR-34a, miR-455-3p, miR-595, miR-1301, miR-146-5p, 193a-5p, miR-939) were found to be significantly associated with the clinicopathological characteristics (p ≤ 0.001), in our data, but mere not similarly significant when tested against external cohorts. Further validation in comparable cohorts, with microRNA profiled using newest and similar methods are warranted.
UR - http://www.scopus.com/inward/record.url?scp=85107334819&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0252401
DO - 10.1371/journal.pone.0252401
M3 - Journal article
C2 - 34086724
AN - SCOPUS:85107334819
VL - 16
SP - 1
EP - 18
JO - PLoS ONE
JF - PLoS ONE
SN - 1932-6203
IS - 6
M1 - e0252401
ER -
ID: 304280656